使用索塔格利弗洛辛准代谢功能障碍和炎症,在实验HFpEF中逆转了透缩功能障碍
bioRxiv : the preprint server for biology
|December 11, 2025
概括
在小鼠中,使用sotagliflozin的双SGLT1/2抑制改善了心力衰竭与保存的喷射分数 (HFpEF). 它增强了脂肪酸氧化和减少炎症,提供了对心脏代谢益处的机械洞察力.
科学领域:
- 心脏病学 心脏病学
- 代谢性疾病是一种代谢性疾病.
- 药理学 药理学是指药理学的学科.
背景情况:
- 保持喷射分数 (HFpEF) 的心力衰竭很常见,与肥胖,高血压和代谢问题有关.
- SGLT2 抑制剂有利于 HFpEF,但双 SGLT1/2 抑制机制尚不清楚.
研究的目的:
- 在心脏代谢HFpEF的小鼠模型中研究sotagliflozin对SGLT1/2双抑制的机制.
- 阐明索塔格利弗洛辛如何影响心脏代谢和炎症.
主要方法:
- 一种高脂肪饮食和L-NAME诱导了小鼠的HFpEF,这些小鼠接受了sotagliflozin或载体的治疗.
- 评估心脏功能,新陈代谢,基因表达和免疫细胞概况.
主要成果:
- 索塔格利弗洛辛减少了体重增加,改善了葡萄糖耐受性,并增强了心脏脂肪酸氧化.
- 它使透支功能障碍正常化,减少心脏纤维化,并抑制炎症途径和免疫细胞透.
- 系统性炎症标志物也减弱了.
结论:
- 在实验性HFpEF中,用sotagliflozin进行SGLT1/2双抑制为心脏代谢带来了好处.
- 它将新陈代谢重新编程为脂质利用,并减少炎症,准HFpEF中的代谢-炎症轴.
相关概念视频
Heart Failure V: Medical Management
198
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
198
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
879
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
879
Heart Failure VI: Adjunct Therapies
235
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
235
Heart Failure Drugs: Diuretics
764
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
764
Heart Failure II: Pathophysiology
668
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
668
Pathophysiology of Heart Failure
2.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.7K


